Article révisé par les pairs
Titre:
  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
Auteur:Goldhirsch, Aron; Gelber, Richard; Piccart-Gebhart, Martine; de Azambuja, Evandro; Dal Lago, Lissandra; Procter, Marion; McFadden, Eleanor; Suter, Thomas; Jackisch, Christian; Cameron, David A; Weber, Harald H.A.; Heinzmann, Dominik; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, Adrian Murray; Otero-Reyes, Douglas; Song, Santai; Smith, Ian; Leyland-Jones, Brian; Baselga, José
Informations sur la publication:Lancet, 382, 9897, page (1021-1028)
Statut de publication:Publié, 2013
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
Antineoplastic Agents -- administration & dosage -- adverse effects
Breast Neoplasms -- drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Medication Adherence
Middle Aged
Receptor, ErbB-2 -- metabolism
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0140-6736
info:doi/10.1016/S0140-6736(13)61094-6
info:pii/S0140673613610946
info:scp/84884418164
info:pmid/23871490

Documents en relation

DI-fusion